Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
New product line to address the challenge of restrictions on use of plastic straws
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The association has lined up a string of prominent speakers from the government and private sector. Seasoned veterans and industry bigwigs will grace the two-day event in Mumbai
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Subscribe To Our Newsletter & Stay Updated
